Home / Pharmaceuticals / Generic Oncology Drugs Market By Molecule Type (Small Molecule and Large Molecule) - Growth, Future Prospects & Competitive Analysis, 2018 - 2026

Generic Oncology Drugs Market By Molecule Type (Small Molecule and Large Molecule) - Growth, Future Prospects & Competitive Analysis, 2018 - 2026

Published: Apr 2019 | Report Code: 59653-04-19

Industry Outlook

The generic oncology drugs market is set to reach from US$ 17,151.0 Mn in 2017 to US$ 29,222.5 Mn by 2026 representing undeviated growth at a compounded annual growth rate (CAGR) of 6.1% during the forecast period from 2018 to 2026. According to the statistics provided by World Health Organization (WHO) in 2018, 9.6 million people worldwide have been estimated to be dead due to cancer. It is considered as the second leading cause of death, researchers are of the opinion that approximately 30% cancer deaths can be prevented by avoiding risk factors such as alcohol consumption, tobacco smoking, early diagnosis etc. Generic oncology drugs drastically reduce the healthcare cost burden associated with cancer treatment, but still there is ambiguity among healthcare professionals regarding its effectiveness and bioequivalence when compared to branded drugs. Healthcare agencies have made it imperative for pharmaceutical companies to follow ICH and cGMP guidelines while manufacturing generic oncology drugs.

Market Synopsis

Generic Oncology Drugs Market

Get a sample copy for more information

"Excellent pharmacokinetic and pharmacodynamic drug profile is related to the positive inclination among oncologist worldwide"

Small molecule are currently dominating the oncology generic drugs market. They apparently constitute for 90% of the medicines currently available in the market. The chief parameters responsible for its popularity among oncologist throughout the globe are its excellent drug pharmacokinetic and pharmacodynamic profile. Large molecules comprises of biologics which are gaining huge traction in the current scenario as they resemble biomolecules present in the human body and specifically binds to those cell receptors which are associated with disease process resulting in high drug efficacy, safety and minimal side effects. Expiry of process patent of biologics employed in cancer treatment will create opportunity for its generic version to enter into market, thereby reducing cost burden associated with cancer.

Generic Oncology Drugs Market

Get a sample copy for more information

"Significant rise in cancer patients and increasing trend of generic substitution over branded drugs drive the market growth in North America"

North America with a market share of 42% is the largest regional market for generic oncology drugs market. According to the research findings of Center for Disease Control and Prevention (CDC), the percent of adults diagnosed with cancer in the United States is 9.4%. The drivers associated with its dominance are rising prevalence of cancer and increasing trend of generic substitution over branded drugs, it is state specific in U.S. and province specific in Canada. Europe holds 30% market share on account of supportive regulatory scenario provided by European Medical Agency (EMA) for generic oncology drugs. Domicile of chief players such as Teva Pharmaceutical Industries, Ltd., Mylan N.V., Merck & Co., and Novartis A.G. further bolster the market growth in Europe. Asia Pacific represents 20% share owing to the significant rise in the number of patients diagnosed with cancer and booming oncology generic market receiving business leverage from government healthcare authorities to reduce the cost burden associated with cancer treatment.

Generic Oncology Drugs Market

Get a sample copy for more information

Historical & Forecast Period

This research report presents the analysis of each segment from 2016 to 2026 considering 2017 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segments are calculated for the forecast period from 2018 to 2026.

Report Scope by Segments

The market is segmented by molecule type and by geography.

ATTRIBUTE DETAILS
Research Period  2017-2027
Base Year 2018
Forecast Period  2019-2027
Historical Year  2017
Unit  USD Million
Segmentation

 By Molecule Type (2016–2026; US$ Mn)
 • Small Molecule
 • Large Molecule

 Geography Segment (2016–2026; US$ Mn)
 • North America (U.S., Canada)
 • Europe (U.K., Germany, Rest of Europe)
 • Asia Pacific (China, Japan, Rest of APAC)
 • Latin America (Brazil, Mexico, Rest of Latin America)
 • Middle East and Africa (GCC, Rest of Middle East and Africa)

Pharmaceutical giants having a strong foothold in the generic oncology drugs market are AstraZeneca, Plc., Bayer Healthcare AG., Celgene Corporation, F.Hoffman-La Roche Ltd., GlaxoSmithkline, Plc., Johnson and Johnson, Merck & Co., Mylan N.V., Novartis AG. and Teva Pharmaceutical Industries, Ltd.

Key questions answered in this report

  • Which pharmaceutical companies are competing in the generic oncology drugs market?
  • What is the SWOT analysis of generic oncology drugs market?
  • What is the prevalence rate of different types of cancer?
  • What will be the performance and market demand of large molecules in the near future?
  • What are the primary factors contributing towards the supremacy of North America in the regional market?

Chapter 1. Preface
1.1. Report Scope and Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Molecule Type
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I-Secondary Research
1.3.2. Phase II-Primary Research
1.3.3. Approach Adopted
1.3.4. Top-down Approach
1.3.5. Bottom-up Approach
1.3.6. Phase III-Expert Panel Review
1.3.7. Assumptions
1.4. Market Segmentation

Chapter 2. Executive Summary
2.1. Global GOD Market Portraiture
2.2. Global GOD Market, by Molecule Type, 2017 (US$ Mn)
2.3. Global GOD Market, by Geography, 2017 (US$ Mn)

Chapter 3. Generic Oncology Drugs (GOD) Market: Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Analysis: Global GOD Market, by Key Players, 2017

Chapter 4. Global Generic Oncology Drugs (GOD) Market, by Molecule Type
4.1. Overview
4.2. Small Molecule
4.3. Large Molecule

Chapter 5. Global Generic Oncology Drugs (GOD) Market, by Geography
5.1. Overview
5.2. North America GOD Market Analysis, 2016 – 2026
5.2.1. North America GOD Market, by Molecule Type, 2016 – 2026 (US$ Mn)
5.2.2. North America GOD Market, by Country, 2016 – 2026 (US$ Mn)
5.2.2.1. U.S.
5.2.2.2. Canada
5.3. Europe GOD Market Analysis, 2016 – 2026
5.3.1. Europe GOD Market, by Molecule Type, 2016 – 2026 (US$ Mn)
5.3.2. Europe GOD Market, by Country/Region, 2016 – 2026 (US$ Mn)
5.3.2.1. U.K.
5.3.2.2. Germany
5.3.2.3. Rest of Europe
5.4. Asia Pacific GOD Market Analysis, 2016 – 2026
5.4.1. Asia Pacific GOD Market, by Molecule Type, 2016 – 2026 (US$ Mn)
5.4.2. Asia Pacific GOD Market, by Country/Region, 2016 – 2026 (US$ Mn)
5.4.2.1. China
5.4.2.2. Japan
5.4.2.3. Rest of Asia Pacific
5.5. Latin America GOD Market Analysis, 2016 – 2026
5.5.1. Latin America GOD Market, by Molecule Type, 2016 – 2026 (US$ Mn)
5.5.2. Latin America GOD Market, by Country/Region, 2016 – 2026 (US$ Mn)
5.5.2.1. Brazil
5.5.2.2. Mexico
5.5.2.3. Rest of Latin America
5.6. Middle East & Africa GOD Market Analysis, 2016 – 2026
5.6.1. MEA GOD Market, by Molecule Type, 2016 – 2026 (US$ Mn)
5.6.2. MEA GOD Market, by Region, 2016 – 2026 (US$ Mn)
5.6.2.1. GCC
5.6.2.2. Rest of MEA

Chapter 6. Company Profiles
6.1. AstraZeneca, Plc.
6.1.1. Business Description
6.1.2. Financial Information (Subject to data availability)
6.1.3. Product Portfolio
6.1.4. News Coverage
6.2. Bayer Healthcare AG.
6.3. Celgene Corporation
6.4. F.Hoffman-La Roche Ltd.
6.5. GlaxoSmithKline, Plc.
6.6. Johnson and Johnson
6.7. Merck & Co.
6.8. Mylan N.V.
6.9. Novartis AG.
6.10. Teva Pharmaceutical Industries, Ltd.

* GOD - Generic Oncology Drugs

FIG. 1 : Generic Oncology Drugs (GOD) Market: Research Methodology
FIG. 2 : GOD: Market Segmentation
FIG. 3 : Global GOD Market, by Molecule Type, 2017 (US$ Mn)
FIG. 4 : Global GOD Market, by Geography, 2017 (US$ Mn)
FIG. 5 : Attractive Investment Proposition: by Geography, 2017
FIG. 6 : Competitive Analysis: Global GOD Market, by Key Players, 2017
FIG. 7 : Global Small Molecule Market for GOD, 2016 – 2026 (US$ Mn)
FIG. 8 : Global Large Molecule Market for GOD, 2016 – 2026 (US$ Mn)
FIG. 9 : U.S. GOD Market, 2016 – 2026 (US$ Mn)
FIG. 10 : Canada GOD Market, 2016 – 2026 (US$ Mn)
FIG. 11 : U.K. GOD Market, 2016 – 2026 (US$ Mn)
FIG. 12 : Germany GOD Market, 2016 – 2026 (US$ Mn)
FIG. 13 : Rest of Europe GOD Market, 2016 – 2026 (US$ Mn)
FIG. 14 : China GOD Market, 2016 – 2026 (US$ Mn)
FIG. 15 : Japan GOD Market, 2016 – 2026 (US$ Mn)
FIG. 16 : Rest of Asia Pacific GOD Market, 2016 – 2026 (US$ Mn)
FIG. 17 : Brazil GOD Market, 2016 – 2026 (US$ Mn)
FIG. 18 : Mexico GOD Market, 2016 – 2026 (US$ Mn)
FIG. 19 : Rest of Latin America GOD Market, 2016 – 2026 (US$ Mn)
FIG. 20 : GCC GOD Market, 2016 – 2026 (US$ Mn)
FIG. 21 : Rest of Middle East and Africa GOD Market, 2016 – 2026 (US$ Mn)

TABLE 1 : Global Generic Oncology Drugs (GOD) Market Portraiture
TABLE 2 : Global GOD Market, by Molecule Type, 2016 – 2026 (US$ Mn)
TABLE 3 : Global GOD Market, by Geography, 2016 – 2026 (US$ Mn)
TABLE 4 : North America GOD Market, by Molecule Type, 2016 – 2026 (US$ Mn)
TABLE 5 : North America GOD Market, by Country, 2016 – 2026 (US$ Mn)
TABLE 6 : Europe GOD Market, by Molecule Type, 2016 – 2026 (US$ Mn)
TABLE 7 : Europe GOD Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 8 : Asia Pacific GOD Market, by Molecule Type, 2016 – 2026 (US$ Mn)
TABLE 9 : Asia Pacific GOD Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 10 : Latin America GOD Market, by Molecule Type, 2016 – 2026 (US$ Mn)
TABLE 11 : Latin America GOD Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 12 : Middle East and Africa GOD Market, by Molecule Type, 2016 – 2026 (US$ Mn)
TABLE 13 : Middle East and Africa GOD Market, by Region, 2016 – 2026 (US$ Mn)
TABLE 14 : AstraZeneca, Plc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 15 : Bayer Healthcare AG.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 16 : Celgene Corporation: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 17 : F.Hoffman-La Roche Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 18 : GlaxoSmithkline, Plc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 19 : Johnson and Johnson: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 20 : Merck & Co.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 21 : Mylan N.V.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 22 : Novartis AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 23 : Teva Pharmaceutical Industries, Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)

Choose License Type
Connect With Us
+1-800-361-8290
24/7 Research Support

Our Clients